AU2017281742B2 - Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors - Google Patents

Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors Download PDF

Info

Publication number
AU2017281742B2
AU2017281742B2 AU2017281742A AU2017281742A AU2017281742B2 AU 2017281742 B2 AU2017281742 B2 AU 2017281742B2 AU 2017281742 A AU2017281742 A AU 2017281742A AU 2017281742 A AU2017281742 A AU 2017281742A AU 2017281742 B2 AU2017281742 B2 AU 2017281742B2
Authority
AU
Australia
Prior art keywords
compound
ilb
nmr
cdcl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017281742A
Other languages
English (en)
Other versions
AU2017281742A1 (en
Inventor
Adam Bucki
Adrian Newman-Tancredi
Joanna SNIECIKOWSKA
Mark Andrew Varney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurolixis
Universite Jagellonne
Original Assignee
Neurolixis
Jagellonne, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurolixis, Jagellonne, University of filed Critical Neurolixis
Publication of AU2017281742A1 publication Critical patent/AU2017281742A1/en
Application granted granted Critical
Publication of AU2017281742B2 publication Critical patent/AU2017281742B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2017281742A 2016-06-24 2017-06-23 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors Active AU2017281742B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305769.8 2016-06-24
EP16305769.8A EP3260452A1 (en) 2016-06-24 2016-06-24 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors
PCT/EP2017/065585 WO2017220799A1 (en) 2016-06-24 2017-06-23 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors

Publications (2)

Publication Number Publication Date
AU2017281742A1 AU2017281742A1 (en) 2019-01-03
AU2017281742B2 true AU2017281742B2 (en) 2021-01-07

Family

ID=56404042

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017281742A Active AU2017281742B2 (en) 2016-06-24 2017-06-23 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors

Country Status (9)

Country Link
US (1) US10562853B2 (enExample)
EP (2) EP3260452A1 (enExample)
JP (1) JP6935873B2 (enExample)
CN (1) CN109563073B (enExample)
AU (1) AU2017281742B2 (enExample)
CA (1) CA3028036A1 (enExample)
DK (1) DK3475268T3 (enExample)
ES (1) ES2831853T3 (enExample)
WO (1) WO2017220799A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874616B (zh) * 2025-03-28 2025-05-30 四川美域高生物医药科技有限公司 一种有机中间体及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022459A1 (fr) * 1996-11-21 1998-05-28 Pierre Fabre Medicament Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
WO2000021953A1 (fr) * 1998-10-09 2000-04-20 Pierre Fabre Medicament Derives d'aryl-{4-fluoro-4-[(2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl}-methanone comme agonistes du recepteur 5-ht1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702211B1 (fr) * 1993-03-04 1995-06-02 Pf Medicament Nouveaux dérivés de la phénoxy-2 éthylamine, leur préparation et leur application en thérapeutique.
EP2058306A1 (en) * 2007-11-08 2009-05-13 Schwarz Pharma Ag Heteroaryl-substituted 2-pyridinyl-methylamine derivatives
PL395470A1 (pl) * 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022459A1 (fr) * 1996-11-21 1998-05-28 Pierre Fabre Medicament Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
WO2000021953A1 (fr) * 1998-10-09 2000-04-20 Pierre Fabre Medicament Derives d'aryl-{4-fluoro-4-[(2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl}-methanone comme agonistes du recepteur 5-ht1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VACHER B ET AL, "DESIGN AND SYNTHESIS OF A SERIES OF 6-SUBSTITUTED-2-PYRIDINYLMETHYLAMINE DERIVATIVES AS NOVEL, HIGH-AFFINITY, SELECTIVE AGONISTS AT 5-HT1A RECEPTORS", J. MED. CHEM., (1998), vol. 41, no. 25, pages 5070 - 5083 *

Also Published As

Publication number Publication date
JP2019519615A (ja) 2019-07-11
US20190194132A1 (en) 2019-06-27
WO2017220799A1 (en) 2017-12-28
US10562853B2 (en) 2020-02-18
EP3475268B9 (en) 2021-04-21
EP3260452A1 (en) 2017-12-27
JP6935873B2 (ja) 2021-09-15
AU2017281742A1 (en) 2019-01-03
DK3475268T3 (da) 2020-10-26
EP3475268A1 (en) 2019-05-01
CA3028036A1 (en) 2017-12-28
ES2831853T3 (es) 2021-06-09
CN109563073A (zh) 2019-04-02
CN109563073B (zh) 2021-12-07
EP3475268B1 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
JP5335932B2 (ja) 制癌剤である二置換ピリジン誘導体
KR102566864B1 (ko) 아릴- 또는 헤테로아릴-치환된 벤젠 화합물
CA2904618C (en) Substituted 2-azabicycles and their use as orexin receptor modulators
EP1954696B1 (en) 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
WO2022135572A1 (zh) 一种五并五元环衍生物及其在医药上的应用
CN103717593B (zh) 调节激酶的组合物和方法
CN101014571A (zh) 用作hiv整合酶抑制剂的n－苄基－3,4－二羟基吡啶－2－羧酰胺类和n－苄基－2,3－二羟基吡啶－4－羧酰胺类化合物
JP2021522253A (ja) 化合物及びその使用
JP2022544714A (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
CA2984290C (en) Benzimidazolone and benzothiazolone compounds and their use as ampa receptor modulators
CA3021185C (en) Fused heterocyclic compound
AU2013253541A1 (en) Quinazolinedione derivative
JP7642859B2 (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾールチオカルボニル化合物およびこれを含む薬剤学的組成物
AU2017281742B2 (en) Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors
JP2013047223A (ja) 医薬
CN102066328A (zh) 亚氨基吡啶衍生物及其用途
HK40007735A (en) Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors
HK40007735B (en) Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors
Frazier et al. Synthesis of diversely substituted pyridin-2 (1 H)-ones and in vivo evaluation of their anti-allodynic effect on cutaneous inflammatory mechanical allodynia
NZ793902A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
WO2021168521A1 (en) Inhibitors of necroptosis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)